RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs). Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors in adults.
This information follows the recent news that the Centers for Medicare & Medicaid Services (CMS) has simplified the coding for Detectnet. Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients. While Transitional Pass-Through Status remains in effect for Detectnet, C9068 was replaced with A9592 beginning April 1, 2021.
“We are grateful that the NCCN acted quickly to include Detectnet in their Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors,” said Curium Vice President of Marketing, North America, Michael Patterson. “This agent is the only ready-made PET somatostatin receptor targeted diagnostic widely available throughout the U.S. Our unique manufacturing and distribution capabilities allow us to provide a reliable supply of Detectnet to physicians and imaging centers serving neuroendocrine patients regardless of geography.”
“Neuroendocrine cancer continues to be an area of research for RadioMedix,” said Ebrahim Delpassand, MD, CEO of RadioMedix. “The Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet. Further, the 12.7 hour half-life of Detectnet enables it to be produced centrally and shipped to sites throughout the U.S, which is particularly important as we continue to navigate through the pandemic. We are pleased the NCCN members have updated their Clinical Practice Guidelines to reflect the important clinical utility of Detectnet.”
About Detectnet
INDICATIONS
Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
IMPORTANT RISK INFORMATION
WARNINGS AND PRECAUTIONS
Radiation Risk
Diagnostic radiopharmaceuticals, including Detectnet, contribute to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
Risk for Image Misinterpretation
The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors. Increased uptake might also be seen in other non-cancerous pathologic conditions that express somatostatin receptors including thyroid disease or in subacute inflammation, or might occur as a normal physiologic variant (e.g. uncinate process of the pancreas).
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
ADVERSE REACTIONS
In clinical trials, adverse reactions occurred at a rate of < 2% and included nausea, vomiting and flushing. In published trials nausea immediately after injection was observed.
DRUG INTERACTIONS
Somatostatin Analogs
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2). Image patients just prior to dosing with somatostatin analogs. For patients on long-acting somatostatin analogs, a wash-out period of 28 days is recommended prior to imaging. For patients on short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging.
USE IN SPECIFIC POPULATIONS
Pregnancy
All radiopharmaceuticals, including Detectnet, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of Detectnet.
Lactation
Advise a lactating woman to interrupt breastfeeding for 12 hours after Detectnet administration in order to minimize radiation exposure to a breastfed infant.
Pediatric use
The safety and effectiveness of Detectnet have not been established in pediatric patients.
Geriatric use
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
OVERDOSAGE
In the event of a radiation overdose, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by reinforced hydration and frequent bladder voiding. A diuretic might also be considered. Please see Full prescribing information by clicking here.
About RadioMedix
RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals. RadioMedix has also established contract service facilities for academic and industrial partners: Full cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing of the radiopharmaceuticals, and probe development and small animal Molecular Imaging Facility for pre-clinical evaluation of radiopharmaceuticals in animal models. To learn more, visit www.radiomedix.com. For more information about this press release, please contact: media@radiomedix.com
About Curium
Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com. For more information about this press release, please contact Janet Ryan, media contact for Curium: janet@ryan-pr.com.
About Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract, pancreas and liver, but can also occur in other tissues including lung, thymus and other uncommon sites such as cervix, heart and prostate. Most NETs strongly express somatostatin receptors (SSTRs).
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Renewables and nascent low-carbon technologies most exposed to high interest rates18.4.2024 12:25:00 CEST | Press release
NEWS RELEASE Renewables and nascent low-carbon technologies most exposed to high interest rates Policymakers should focus on bolstering carbon markets, maximising subsidy efficiency and mobilising green finance LONDON, 18 April 2024 – If high interest rates persist, transitioning to a net zero global economy will be even harder and more costly. The higher cost of borrowing negatively affects renewables and nascent technologies, compared to more established oil and gas, and metals and mining sectors, which remain somewhat insulated, according to latest report: ‘Conflicts of interest: the cost of investing in the energy transition in a high interest-rate era’ by Wood Mackenzie. “Interest rates, which have risen sharply in the past two years, may not come down as far or as quickly as markets anticipate. This increased cost of capital has profound implications for the energy and natural resource industries, particularly the cost and pace of the transition to low-carbon technologies,” said
Storaktionærmeddelelse18.4.2024 12:01:52 CEST | pressemeddelelse
Selskabsmeddelelse nr. 18/2024 Holbæk, den 18. april 2024 Storaktionærmeddelelse Fonden for Sparekassen Sjælland har meddelt, at grundet Sparekassen Sjælland-Fyn A/S’s kapitalnedsættelse ejer fonden nu 5,08 % af aktiekapitalen i Sparekassen Sjælland-Fyn A/S. Med venlig hilsen Lars Petersson Jakob Andersson Adm. direktør Formand Yderligere information: Presse- og direktionsrådgiver Morten Huse Eikrem-Jeppesen, tlf. 53 85 07 70 Administrerende direktør Lars Petersson Sparekassedirektør Lars Bolding www.spks.dk/ir Vedhæftet fil Selskabsmeddelelse nr. 18 - 2024 - Storaktionærmeddelelse
CNH to release 2024 First Quarter financial results on May 218.4.2024 12:00:00 CEST | Press release
CNH to release 2024 First Quarter financial results on May 2 Basildon, April 18, 2024 CNH (NYSE: CNHI) will release its 2024 First Quarter financial results on Thursday, May 2, 2024. A live audio webcast of the financial results conference call will begin at 9:00 a.m. EDT (2:00 p.m. BST / 3:00 p.m. CEST) on the same day. It will be accessible at the following address: bit.ly/CNH_Q1_2024 For those unable to participate in the live session, a replay will remain archived in the Investor Relations section of the corporate website (www.cnh.com) for two weeks following the conference call. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland supply 360° agriculture applications from machines
Extraordinary General Meeting of Jyske Bank A/S held on 18 April 202418.4.2024 11:55:43 CEST | Press release
At the Extraordinary General Meeting of Jyske Bank held today, the motions set out in the agenda were finally adopted. The motions about amendments to the Articles of Association proposed by the Supervisory Board under items a.1 – a.4 of the agenda (concerning the remuneration structure for the Shareholders' Representatives, election of Supervisory Board members and handling of the salary and pension terms of the Executive Board) as well as the motion under item b of the agenda concerning the authorisation of the general meeting to the Supervisory Board for registration of the Articles of Association were all adopted. The Danish Business Authority is subsequently requested to register the adopted motions. Yours faithfully, Jyske Bank Contact person: CFO, Birger Krøgh Nielsen, phone +45 89 89 64 44. Attachment EGM_20240418
Ekstraordinær generalforsamling i Jyske Bank A/S den 18. april 202418.4.2024 11:55:43 CEST | pressemeddelelse
På bankens ekstraordinære generalforsamling d.d. blev forslagene ifølge dagsordenen endelig vedtaget. Forslagene om vedtægtsændringer fremsat af bestyrelsen under dagsordenens pkt. a.1 – a.4 (vedr. vederlagsstrukturen for repræsentantskabet, valg af bestyrelsesmedlemmer og håndtering af direktionens lønnings- og pensionsvilkår) samt forslaget under dagsordenens pkt. b vedrørende generalforsamlingens bemyndigelse til bestyrelsen til brug for vedtægternes registrering blev alle vedtaget. Erhvervsstyrelsen anmodes herefter om registrering af det vedtagne. Venlig hilsen Jyske Bank Kontaktperson: CFO, Birger Krøgh Nielsen, telefon +45 89 89 64 44. Vedhæftet fil EOGF_20240418